1416 related articles for article (PubMed ID: 17372174)
1. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
3. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
6. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
7. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
8. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
9. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
10. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
11. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
13. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
Origa R; Bina P; Agus A; Crobu G; Defraia E; Dessì C; Leoni G; Muroni PP; Galanello R
Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
[TBL] [Abstract][Full Text] [Related]
15. T2* magnetic resonance and myocardial iron in thalassemia.
Pennell DJ
Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
[TBL] [Abstract][Full Text] [Related]
16. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
17. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Kolnagou A; Natsiopoulos K; Kleanthous M; Ioannou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
20. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
